Abstract: A hand-held power tool includes a housing in which a drive unit and an impact-mechanism unit are arranged. The hand-held power tool further includes a tool-receiver interface configured to releasably connect with a tool receiver, the tool receiver configured as a stirrer-basket receiver. A user interface is configured to set at least one of a rotary-hammer mode and a stirring mode for the hand-held power tool.

Abstract: The disclosed computer-implemented method may include systems for generating personalized avatar reactions during live video broadcasts. For example, the systems and methods described herein can access a social networking system user's profile to identify an avatar associated with the social networking system user. The systems and methods can generate an avatar reaction by modifying one or more features of the avatar based on a corresponding emoticon reaction. Once generated, the social networking system user can select the avatar reaction for addition to an ephemeral reaction stream associated with a live video broadcast. Various other methods, systems, and computer-readable media are also disclosed.

Abstract: Methods and apparatuses for generating and displaying a model of a subject's teeth. Described herein are intraoral scanning methods and apparatuses for generating a three-dimensional model of a subject's intraoral region (e.g., teeth). These methods and apparatuses may be used for identifying and evaluating lesions, caries and cracks in the teeth.

Abstract: A glucagon analogue containing a lactam bridge between a Lysine introduced at position 13 and a Glutamic Acid introduced at position 17, optionally including C-terminal extensions and optionally including a second side-chain/side-chain staple beginning at or C-terminal to residue 20. The second staple may also be an (i, i+4) lactam bridge, an (i, i+3) disulfide bridge between D-Cysteine and L-Cysteine or an (i, i+7) disulfide bridge between L-Cysteine and L-Cysteine. A fusion protein containing an N-terminal lactam-stabilized glucagon analogue as above and a C-terminal single-chain insulin (SCI) analogue wherein the C domain of the SCI contains 4-11 residues is also disclosed herein. A method of treating a patient with diabetes mellitus comprises the subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the glucagon analogue or glucagon-SCI fusion protein is also provided.

Abstract: A function module for electrical applications and method of making a function module for electrical applications. The function module includes: a functional member having a piercing area with at least one aluminum conductor trace; and an electrical connector having at least one piercing member. The at least one piercing member is configured to pierce through the at least one aluminum conductor trace in an electrically conductive manner and provide a form-fit connection between the functional member and the electrical connector within the piercing area. The functional member and the electrical connector are joined together within the piercing area by means of a solder connection.

Abstract: Intraoral scanning systems for displaying 3D models of a patient's dental arch and near-IR images from the dental arch. These systems may include a wand with one or more image sensors and processors for processing the 3D models and near-IR information. The 3D models may include surface (e.g., color) information and the near-IR images may include information on internal structures, including enamel and dentin.

Abstract: A single-chain insulin analogue comprises the insulin B-chain polypeptide sequence, the insulin A-chain polypeptide sequence, and a connecting polypeptide sequence of 5-11 amino acids linking the C-terminal amino acid of the B-chain polypeptide to the N-terminal amino acid of the A-chain polypeptide. The analogue comprises an acetylated Lys at a location selected from the group consisting of any of the amino acids in the connecting polypeptide, B0-B3, B28-B29 or A14, relative to wild type insulin, or comprises an acetylated amino acid at the N-terminal amino acid of the single-chain insulin analogue. The single-chain insulin analogue may be acylated with a C6-C21 fatty acid, which may be attached to the e-amino group of a unique Lysine residue or the a-amino group of the N-terminal amino acid of the single-chain insulin analogue. The insulin analogue may be used to lower the blood sugar of a patient in need thereof.

Abstract: A method and system provide the ability to autonomously operate an unmanned aerial system (UAS) over long durations of time. The UAS vehicle autonomously takes off from a take-off landing-charging station and autonomously executes a mission. The mission includes data acquisition instructions in a defined observation area. Upon mission completion, the UAS autonomously travels to a target landing-charging station and performs an autonomous precision landing on the target landing-charging station. The UAS autonomously re-charges via the target landing-charging station. Once re-charged, the UAS is ready to execute a next sortie. When landed, the UAS autonomously transmits mission data to the landing-charging station for in situ or cloud-based data processing.

Abstract: A two-chain insulin analogue is provided containing (a) a B chain modified by a C-terminal diol element such that one hydroxyl group substitutes for the C-terminal carboxylate function in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus. Compositions comprising such insulin analogs are used in methods of treating a patient with diabetes mellitus.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: A function module for electrical applications and method of making a function module for electrical applications. The function module includes: a functional member having a piercing area with at least one aluminum conductor trace; and an electrical connector having at least one piercing member. The at least one piercing member is configured to pierce through the at least one aluminum conductor trace in an electrically conductive manner and provide a form-fit connection between the functional member and the electrical connector within the piercing area. The functional member and the electrical connector are joined together within the piercing area by means of a solder connection.

Abstract: A pharmaceutical composition comprises an effective amount of an insulin analogue comprising modified A-chain and B-chain polypeptides. The modified A chain comprises one or more substitutions relative to wild-type human insulin A-chain selected from a Gln, His or Glu substitution at position A8, a Glu or Ala substitution at position A14, and an Ala, Gln, Gly, or Thr substitution at position A21. The modified B-chain polypeptide comprises one or more modifications relative to wild-type human insulin B-chain selected from a deletion of the amino acid or amino acids at position B1, B1 and B2, or B1-B3, an Ala or Glu substitution at position B2, a Glu or Ala substitution at position B3, an Ala substitution at position B4; and a Glu or Lys substitution at position B29. The composition comprises one or more of iloprost, citrate, EDTA and a polyphosphate compound. The composition may be used to treat diabetes.

Abstract: An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120° C. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.

Abstract: A premixed acidic solution contains two single-chain insulin analogues. One has isoelectric point between 6.5 and 8.0 (SCI-A) and the other has isoelectric point between 4.5 and 6.0 (SCI-B), such that biphasic basal and prandial insulin activity is provided on subcutaneous injection. Each protein is an analogue of a mammalian insulin, such as human insulin, with insertion of engineered C domain of length 5-11 residues; the respective C domains of SCI-A and SCI-B may be different. SCI-A contains a Glycine, Alanine, Serine or Glutamine substitution at position A21 and may contain a basic residue at position A8 and Glutamine at position B13. SCI-B may contain a non-beta-branched substitution at position A8, either Alanine or Glutamic Acid at position A14, and substitutions at positions B28 and/or B29 to confer rapid action. A method of treating a patient comprises administering the insulin analogue or a physiologically acceptable salt thereof to a patient.

Abstract: A single-chain insulin analogue containing (i) diverse amino-acid substitutions at position A14; (ii) wild-type or variant residues at positions A8 and A14; and (ii) an engineered C-domain segment of lengths 4-6 containing a specific set of Alanine substitutions and/or deletions derived from the prototype C-domain sequence Glu-Glu-Gly-Pro-Arg-Arg. The analogue may otherwise be an analogue of a mammalian insulin, such as human insulin, may optionally include standard or non-standard modifications that (i) augment the stability of insulin, (ii) cause a shift in the isoelectric point to enhance or impair the solubility of the protein at neutral pH or (iii) reduce cross-binding of the protein to the Type I IGF receptor. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions under acidic or neutral pH values (e.g., pH 3.0-4.2 and 6.5-7.8, respectively) and optionally in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers.

Abstract: A computer-implemented method is provided for estimating state variables of a moving object, which includes: propagating core state variables of the moving object utilizing a recursive Bayesian filter and observation values from sensors from start-up of the moving object; forming, utilizing observation values from one or more additional sensors added after start-up, a covariance matrix of the recursive Bayesian filter; updating the covariance matrix based on observation values formed by at least one additional sensor; and, ascertaining the covariance of the core state variables of the additional sensor at a time after start-up.

Abstract: Disclosed herein are insulin analogues containing a pairwise substitution of cysteine at positions A6 and A11 with selenocysteine residues such that a diselenide bridge forms between these positions. The disleenide bridge of the [SecA6, SecA11] insulin analogues stabilizes the analogue relative to its [CysA6, CysA11] parent structure, providing formulations with extended shelf life at or above room temperature. Also provide are methods of treating diabetes mellitus using the [SecA6, SecA11] insulin analogue.

Abstract: A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at position A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.

Abstract: A hand-held power tool includes a housing in which a drive unit and an impact-mechanism unit are arranged. The hand-held power tool further includes a tool-receiver interface configured to releasably connect with a tool receiver, the tool receiver configured as a stirrer-basket receiver. A user interface is configured to set at least one of a rotary-hammer mode and a stirring mode for the hand-held power tool.

Abstract: A single-chain insulin analogue containing an engineered C-domain segment of lengths 4-11 conforming to the sequence pattern [Asp/Glu]-Ala-An-Ala-Xaa where An designates a sub-segment of 0-7 Alanine residues and where Xaa designates an amino-acid residue selected from the amino acids Alanine, Arginine, Asparagine, Aspartic Acid, Glutamic Acid, Histine, Lysine and Serine. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include standard or non-standard modifications that (i) augment the stability of insulin, (ii) cause a shift in the isoelectric point to enhance or impair the solubilty of the protein at neutral pH or (iii) reduce cross-binding of the protein to the Type I IGF receptor. A method of treating a patient with diabetes mellitus comprising the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient.